---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-131919"
form_type: "8-K"
ticker: null
cik: "0001061027"
company_name: "Viracta Therapeutics, Inc."
filed_at: "2024-11-29T23:59:59+00:00"
generated_at: "2026-05-29T12:34:28.358256+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viracta (VIRX) receives Nasdaq delisting notice; fails bid price and equity rules, plans appeal hearing

## Summary
- Nasdaq delisting notice dated Nov 26 for bid price non-compliance and equity deficiency; 180-day compliance period expired Nov 25.
- Company will appeal to Nasdaq Listing Qualifications Panel to request extension and present plan to regain compliance.
- Appeal stays delisting pending hearing; no guarantee of extension or favorable outcome.
- Company also failed Nasdaq's $2.5M stockholders' equity requirement, reported Nov 21, 2024.

## SEC filing metadata
- accession: 0000950170-24-131919
- form_type: 8-K
- cik: 0001061027
- company_name: Viracta Therapeutics, Inc.
- filed_at: 2024-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061027/000095017024131919/0000950170-24-131919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061027/000095017024131919/virx-20241126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-131919
- JSON: https://secwatch.observer/filing/0000950170-24-131919.json
- Plain text: https://secwatch.observer/filing/0000950170-24-131919.txt

## Key facts
- Listing & Compliance Notices
  Viracta Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: November 26, 2024, the Staff issued a delist determination to the Company (the “Delisting Notice”), indicating that the Company did not satisfy the Minimum Bid Price Requirement by the Compliance Date. The Delisting Notice indicated that the Company was not eligible for a second 180-day extension because it did not comply with the Stockholders’ Equity Requirement. The Company intends to request a hearing (the “Hearing”) before the Nasdaq Listing Qualifications Panel (the “Panel”) to appeal (the “Appeal”) the determination by the Staff, and to present its plan to regain and sustain compliance w
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024131919/0000950170-24-131919-index.htm
- Listing & Compliance Notices
  Viracta Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: November 26, 2024, the Staff issued a delist determination to the Company (the “Delisting Notice”), indicating that the Company did not satisfy the Minimum Bid Price Requirement by the Compliance Date. The Delisting Notice indicated that the Company was not eligible for a second 180-day extension because it did not comply with the Stockholders’ Equity Requirement. The Company intends to request a hearing (the “Hearing”) before the Nasdaq Listing Qualifications Panel (the “Panel”) to appeal (the “Appeal”) the determination by the Staff, and to present its plan to regain and sustain compliance w
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024131919/0000950170-24-131919-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.